Hybio Pharmaceutical Co. Ltd. | Ownership
Companies that own Hybio Pharmaceutical Co. Ltd.
China Asset Management Co., Ltd.
13,358,518
2.27%
0
0.11%
03/31/2018
China Investment Corp. (Investment Management)
10,056,900
1.71%
0
0.05%
03/31/2018
Harvest Fund Management Co., Ltd.
5,844,250
0.99%
0
0.07%
03/31/2018
E Fund Management Co., Ltd.
5,548,348
0.94%
143,100
0.06%
03/31/2018
PICC Asset Management Co., Ltd.
5,297,632
0.9%
5,297,632
0.15%
03/31/2018
The Caisse de dépôt et placement du Québec
3,243,561
0.55%
0
0.01%
12/31/2017
China Southern Asset Management Co., Ltd.
2,228,818
0.38%
-248,400
0.03%
12/31/2017
Fullgoal Fund Management Co., Ltd.
2,053,874
0.35%
-665,600
0.03%
12/31/2017
China Universal Asset Management Co., Ltd.
1,944,489
0.33%
-776,493
0.03%
12/31/2017
Andra AP-fonden
1,541,993
0.26%
1,541,993
0.02%
12/31/2016
| Address |
4/F, Hybio Biomedical Park Office
Shenzhen Guangdong 518057
China
|
|
Employees
|
- |
| Website |
http://www.hybio.com.cn |
| Updated |
07/08/2019 |
| Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet. |
